Alpha-trinositol reduces edema formation at the site of scald injury.
BACKGROUND
The effects of alpha-trinositol (1D-myo-inositol-1,2,6-triphosphate, IP3) on burn-induced edema formation were investigated.


METHODS
Lymph flow (QL; microliter/min) and lymph-to-plasma protein ratio (CL/CP) were monitored in groups of five to six dogs before and 4 hours after (1) a 5-second 100 degrees C or 90 degrees C foot paw scald; (2) IP3 (45 mg/kg intravenous bolus, then a 20 mg/kg/hr infusion) 30 minutes before or after 100 degrees C scald, or 30 minutes after 90 degrees C scald. Hind paw venous pressure was elevated and maintained by outflow restriction until reaching steady state QL and (CL/CP)min. Macromolecular reflection coefficient (1-CL/CP) was measured. Fluid filtration coefficient (Kf; ml/min/mm Hg/100 gm) was calculated. Relative paw weight gain (%) was measured.


RESULTS
Compared with preburn values, scald uniformly produced significant increases in QL, CL/CP, and Kf, IP3 significantly (p < 0.02, ANOVA) reduced paw weight gain when given before, but not after, 100 degrees C burn (41% +/- 5% versus 18% +/- 7% preburn IP3 and 31% +/- 3% postburn IP3). Compared with 90 degrees C burn animals, postburn treatment significantly (p < 0.017) attenuated 4-hour increases in QL (550 +/- 87 versus 252 +/- 29 microliters/min), Kf (0.016 +/- 00 versus 0.007 +/- 00 microliter/min/mm/Hg/100 gm), and relative paw weight gain (28% +/- 3% versus 12% +/- 5%).


CONCLUSIONS
alpha-Trinositol given after a 90 degrees C scald blunted edema formation at the site of scald, likely through reduced transmembrane fluid flux.
Ferrara
J J
JJ
Department of Surgery, Tulane University School of Medicine, New Orleans, La. 70112, USA.
Kukuy
E L
EL
Gilman
D A
DA
Choe
E U
EU
Franklin
E W
EW
Flint
L M
LM
D000704:Analysis of Variance; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001794:Blood Pressure; D002056:Burns / Q000188:drug therapy* / Q000503:physiopathology; D002196:Capillaries / Q000187:drug effects / Q000503:physiopathology; D004285:Dogs; D004487:Edema / Q000209:etiology / Q000517:prevention & control*; D006614:Hindlimb / Q000098:blood supply; D007295:Inositol Phosphates / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008196:Lymph / Q000187:drug effects / Q000502:physiology; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007295:Inositol Phosphates; C059368:atrinositol